Antiproliferative effects of SOM230 in EPN prostate cell line

被引：0
|
作者：
Rossi, V
Pasquali, D
Gazzerro, G
Abbondanza, C
Bellastella, A
Puca, GA
Sinisi, AA
机构：
[1] Univ Naples 2, Dip Internist Clin & Sperimentale, Naples, Italy
[2] Univ Naples 2, Dip Patol Gen, Naples, Italy
来源：
EUROPEAN JOURNAL OF ENDOCRINOLOGY | 2005年 / 152卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients
    van der Hoek, J
    van der Lelij, AJ
    Feelders, RA
    de Herder, WW
    Uitterlinden, P
    Poon, KW
    Boerlin, V
    Lewis, I
    Krahnke, T
    Hofland, LJ
    Lamberts, SW
    CLINICAL ENDOCRINOLOGY, 2005, 63 (02) : 176 - 184
  • [32] Preclinical and clinical experience with SOM230 a novel multi-ligand somatostatin analog
    Tran, Ly-Le
    Schmid, Herbert A.
    ANNALS OF ONCOLOGY, 2004, 15 : 110 - 110
  • [33] Immunomodulatory effects of SOM 230
    Mastrotto, C.
    Casnici, C.
    Lattuada, D.
    Crotta, K.
    Franco, P.
    Marelli, O.
    JOURNAL OF NEUROIMMUNOLOGY, 2006, 178 : 172 - 172
  • [34] Somatostatin analogue pasireotide (SOM230) inhibits catecholamine secretion in human pheochromocytoma cells
    Streit, Laura
    Moog, Sophie
    Hugel, Sylvain
    Rame, Marion
    Tanguy, Emeline
    Andry, Virginie
    Schmid, Herbert A.
    Brunaud, Laurent
    Bihain, Florence
    Nomine-Criqui, Claire
    Goumon, Yannick
    Lacomme, Stephanie
    Lomazzi, Sandra
    Vix, Michel
    Mutter, Didier
    Vitale, Nicolas
    Ory, Stephane
    Gasman, Stephane
    CANCER LETTERS, 2022, 524 : 232 - 244
  • [35] The Synergistic Effect of Pasireotide (SOM230) and a Raf-1 Activating Agent in Carcinoids
    Somnay, Yash
    Chen, Herbert
    Kunnimalaiyaan, Muthusamy
    PANCREAS, 2012, 41 (02) : 341 - 341
  • [36] Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma
    Feun, Lynn G.
    Wangpaichitr, Medhi
    Li, Ying-Ying
    Kwon, Deukwoo
    Richman, Stephen P.
    Hosein, Peter J.
    Savaraj, Niramol
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2018, 5 : 9 - 15
  • [37] Short- and long-term effects of pasireotide (SOM230) and octreotide on plasma glucose, insulin and glucagon in rats
    Schmid, HA
    Silva, AP
    NEUROENDOCRINOLOGY, 2006, 83 (01) : 62 - 62
  • [38] Trattamento con pasireotide (SOM230) nella malattia di CushingTreatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial
    M. Boscaro
    W. H. Ludlam
    B. Atkinson
    J. E. Glusman
    S. Petersenn
    M. Reincke
    P. Snyder
    A. Tabarin
    B. M. K. Biller
    J. Findling
    S. Melmed
    C. H. Darby
    K. Hu
    Y. Wang
    P. U. Freda
    A. B. Grossman
    L. A. Frohman
    J. Bertherat
    Emanuela Arvat
    L’Endocrinologo, 2009, 10 (1) : 42 - 43
  • [39] Effect of SOM230 (Pasireotide) on Corticotropic Cells: Action in Dogs with Cushing's Disease
    Castillo, Victor
    Theodoropoulou, Marily
    Stalla, Johanna
    Gallelli, Maria Florencia
    Cabrera-Blatter, Maria Fernanda
    Haedo, Mariana R.
    Labeur, Marta
    Schmid, Herbert A.
    Stalla, Guenter K.
    Arzt, Eduardo
    NEUROENDOCRINOLOGY, 2011, 94 (02) : 124 - 136
  • [40] Expression of Somatostatin Receptors in Human Melanoma Cell Lines: Effect of Two Different Somatostatin Analogues, Octreotide and SOM230, on Cell Proliferation
    Martinez-Alonso, M.
    Llecha, N.
    Mayorga, M. E.
    Sorolla, A.
    Dolcet, X.
    Sanmartin, V.
    Abal, L.
    Casanova, J. M.
    Baradad, M.
    Yeramian, A.
    Egido, R.
    Puig, S.
    Vilella, R.
    Matias-Guiu, X.
    Marti, R. M.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2009, 37 (06) : 1813 - 1822
12345